A study evaluating impact of diabetes on outcomes of sorafenib therapy for hepatocellular carcinoma.
Phase of Trial: Phase IV
Latest Information Update: 26 Oct 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Oct 2017 Primary end point (Overall survival) has been met as per the results published in the Targeted Oncology.
- 26 Oct 2017 New trial record